Results 121 to 130 of about 3,026 (154)

Fidaxomicin

Hospital Pharmacy, 2011
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
J. Cada Dennis, L. Levien Terri, E. Baker Danial   +2 more
openaire   +3 more sources

Probable fidaxomicin-induced pancytopenia

American Journal of Health-System Pharmacy, 2018
A case of pancytopenia in a patient receiving treatment with fidaxomicin for Clostridium difficile infection (CDI) is described.A 33-year-old Caucasian woman was admitted to the hospital with a chief complaint of loose stools occurring approximately 7 times a day; she also reported fever, nausea, diffuse abdominal pain, and fatigue.
Samantha, Axtell, Aisha, Shokoya, Christine, Yocum   +2 more
openaire   +2 more sources

Fidaxomicin: Balancing evidence and economics

American Journal of Health-System Pharmacy, 2012
Over the past 10 years, Clostridium difficile infection (CDI) has become a leading cause of nosocomial infection and a significant source of health care expenditures in the United States. The standard therapies for CDI—oral vancomycin and metronidazole—are both associated with significant ...
Vanessa, Stevens, Nikolas, Onufrak, Jack, Brown   +2 more
openaire   +2 more sources

Fidaxomicin: first-in-class macrocyclic antibiotic

Expert Review of Anti-infective Therapy, 2011
The incidence of Clostridium difficile has doubled over the past 15 years, and rising mortality rates associated with this infection have followed in its wake. C. difficile infection (CDI) has supplanted methicillin-resistant Staphylococcus aureus as the major cause of nosocomial infection.
Kathleen M, Mullane, Sherwood, Gorbach
openaire   +2 more sources